Opening book details…
Can I read Adoption of Lutetium-^177^ PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020 on EtoBox?
Adoption of Lutetium-^177^ PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020 by Luka Flegar; Smita George Thoduka; Damiano Librizzi; Markus Luster; Aristeidis Zacharis; Hendrik Heers; Nicole Eisenmenger; Hojjat Ahmadzadehfar; Matthias Eiber; Wolfgang Weber; Christer Groeben; Johannes Huber is a Medicine article available to read on EtoBox.
What is Adoption of Lutetium-^177^ PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020 about?
## Purpose This study is to investigate the adoption and current trends of Lutetium-^177^ PSMA RLT for mCRPC in Germany. ## Methods We analyzed data from the reimbursement.INFO tool based on German hospitals’ quality reports for Lutetium-^177^ PSMA RLT from 2016 to 2020 and from the nationwide German hospital billing database (Destatis) for general therapy with open radionuclides in combination with prostate cancer from 2006 to 2020. For validation of these billing data, we included the ^177^Lu-PSMA RLT cycles from two participating institutions from 2016 to 2020. For detection of trends over time we applied linear regression models. ## Results General therapy with open radionuclides increased from 2006 to 2020. We identified a total of 12,553 ^177^Lu-PSMA RLT cycles. The number of ^177^Lu-PSMA RLTs steadily increased from a total of 1026 therapies in 2016 to 3328 therapies in 2020 (+ 576 RLT/year; __p__ < 0.005). In 2016, 25 departments of nuclear medicine offered this treatment, which increased to 44 nuclear medicine departments in 2020. In 2016, 16% of nuclear medicine departments (4/25) performed more than 100 ^177^Lu-PSMA RLTs, which increased to 36% (16/44) in 2020 (__p__ < 0
Who reads Adoption of Lutetium-^177^ PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Luka Flegar; Smita George Thoduka; Damiano Librizzi; Markus Luster; Aristeidis Zacharis; Hendrik Heers; Nicole Eisenmenger; Hojjat Ahmadzadehfar; Matthias Eiber; Wolfgang Weber; Christer Groeben; Johannes Huber
- Publisher
- Springer Science and Business Media LLC
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)